Syndax Pharmaceuticals struggles with competitive pressures and market skepticism despite promising drugs and strong cash position. Read more on SNDX here.

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.